Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02043587 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
A Phase 2 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT02043587 is a Phase 2 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 31 participants.
The verdict
NCT02043587, a Phase 2 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The objective of this protocol is to improve survival for adults with acute lymphoblastic leukemia or acute lymphoblastic lymphoma by reducing systemic and central nervous system (CNS) relapse with acceptable toxicity using intensive chemotherapy with liposomal cytarabine (Depocyt®) CNS prophylaxis.
Interventions
- DRUG Prednisone
- DRUG DNR
- DRUG VCR
- DRUG PEG-asp
- DRUG CTX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-01 |
| Est. Completion | 2022-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02043587
The ClinicalTrials.gov registry entry for NCT02043587 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Prednisone is the first listed.
NCT02043587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02043587 about?
NCT02043587 is a clinical study titled "Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma". The objective of this protocol is to improve survival for adults with acute lymphoblastic leukemia or acute lymphoblastic lymphoma by reducing systemic and central nervous system (CNS) relapse with acceptable toxicity using intensive chemotherapy with liposomal cytarabine (Depocyt®) CNS prophylaxis.
What is the current status of trial NCT02043587?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2014-01. Estimated completion is 2022-04-14.
What interventions are being tested in trial NCT02043587?
The interventions under investigation include: Prednisone (DRUG), DNR (DRUG), VCR (DRUG), PEG-asp (DRUG), CTX (DRUG).
Who is sponsoring clinical trial NCT02043587?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.